Tracer library / [212Pb]Pb-VMT-alpha-NET

[212Pb]Pb-VMT-alpha-NET

Also written as [212Pb]Pb-VMT-alpha-NET
Radionuclide
Pb-212
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
0
Neuroendocrine neoplasmsDosimetry and biodistribution studiesPeptide receptor radionuclide therapy

What it is

Compound class
Peptide-based somatostatin analog conjugate (DO3A-type lead-specific chelator conjugated to Tyr3-octreotide via PEG linker)
Target / mechanism
Somatostatin receptor type 2 (SSTR2) PMID 41644295
Clinical application
Refractory or relapsed metastatic neuroendocrine tumors PMID 41644295
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET.
    2026 · J Nucl Med · Clinical study

Need this precursor?We can point you to suppliers for [212Pb]Pb-VMT-alpha-NET, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 37652545, 41644295. Stage set/updated at stage 39 from PMID 41644295: 'is currently in early-phase clinical trials for patients with neuroendocrine tumors (NETs)'.